XML 56 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Unaudited Quarterly Financial Information (Tables)
12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information [Table Text Block]
The following is a summary of our unaudited quarterly results for the years ended December 31, 2019 and 2018 (in thousands):
 
 
Quarter Ended
2019 (Unaudited):
 
March 31,
 
June 30,
 
September 30,
 
December 31,
Total revenues (1)
 
$
56,949

 
$
39,148

 
$
46,230

 
$
53,665

Gross profit on product sales
 
$
3,741

 
$
3,883

 
$
6,872

 
$
6,006

Total operating expenses(3)
 
$
53,983

 
$
53,125

 
$
70,767

 
$
85,727

Net Income (loss)
 
$
1,796

 
$
(14,624
)
 
$
(25,015
)
 
$
(34,397
)
Net Income (loss) per share:
 
 
 
 
 
 
 
 
Basic
 
$
0.01

 
$
(0.10
)
 
$
(0.17
)
 
$
(0.24
)
Diluted
 
$
0.01

 
$
(0.10
)
 
$
(0.17
)
 
$
(0.24
)
Shares used in computing net income (loss) per share:
 
 
 
 
 
 
 
 
Basic
 
144,743

 
145,411

 
146,136

 
141,046

Diluted
 
147,474

 
145,411

 
146,136

 
141,046

 
 
Quarter Ended
2018 (Unaudited):
 
March 31,
 
June 30,
 
September 30,
 
December 31,
Total revenues (2)
 
$
30,872

 
$
35,202

 
$
25,556

 
$
60,232

Gross profit on product sales
 
$
3,749

 
$
3,647

 
$
5,643

 
$
5,059

Total operating expenses
 
$
54,584

 
$
55,275

 
$
51,030

 
$
60,303

Net loss
 
$
(27,461
)
 
$
(22,893
)
 
$
(27,850
)
 
$
(2,126
)
Net loss per share:
 
 
 


 


 


Basic
 
$
(0.19
)
 
$
(0.16
)
 
$
(0.19
)
 
$
(0.01
)
Diluted
 
$
(0.19
)
 
$
(0.16
)
 
$
(0.19
)
 
$
(0.01
)
Shares used in computing net loss per share:
 


 


 


 


Basic
 
142,656

 
143,568

 
143,949

 
144,203

Diluted
 
142,656

 
143,568

 
143,949

 
144,203

_______________
(1)
Revenue for the quarter ended March 31, 2019 included $30.0 million in revenue under a collaborative arrangement from argenx.
(2)
Revenues for the quarter ended December 31, 2018 included $30.0 million in revenue under a collaborative arrangement from Roche.
(3)
Total operating expenses for the quarter ended December 31, 2019 included $28.4 million restructuring charges.